Daniel Åberg1, Per Johansson1,2, Jörgen Isgaard1,3, Anders Wallin4, Jan-Ove Johansson1, Ulf Andreasson4, Kaj Blennow4, Henrik Zetterberg4,5, N David Åberg1, Johan Svensson1,6. 1. Department of Internal Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. 2. Department of Neuropsychiatry, Skaraborg Hospital, Falköping, Sweden. 3. School of Medicine and Public Health, Faculty of Health and Medicine, University of Newcastle, NSW, Australia. 4. Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden. 5. UCL Institute of Neurology, Queen Square, London, UK. 6. Department of Endocrinology, Skaraborg Hospital, Skövde, Sweden.
Abstract
BACKGROUND: Insulin-like growth factor-II (IGF-II) is important for brain development. Although IGF-II is abundant also in adult life, little is known of the role of IGF-II in Alzheimer's disease (AD). OBJECTIVE AND METHODS: This was a cross-sectional study of 60 consecutive patients under primary evaluation of cognitive impairment and 20 healthy controls. The patients had AD dementia or mild cognitive impairment (MCI) diagnosed with AD dementia upon follow-up (n = 32), stable MCI (SMCI, n = 13), or other dementias (n = 15). IGF-II, IGF-binding protein-1 (IGFBP-1), and IGFBP-2 were analyzed in serum and cerebrospinal fluid (CSF). RESULTS: Levels of IGF-II, IGFBP-1, and IGFBP-2 were similar in all groups in the total study population. Gender-specific analyses showed that in men (n = 40), CSF IGF-II level was higher in AD compared to SMCI and controls (p < 0.01 and p < 0.05, respectively). Furthermore, CSF IGFBP-2 level was increased in AD men versus SMCI men (p < 0.01) and tended to be increased versus control men (p = 0.09). There were no between-group differences in women (n = 40). In the total study population (n = 80) as well as in men (n = 40), CSF levels of IGF-II and IGFBP-2 correlated positively with CSF levels of the AD biomarkers total-tau and phosphorylated tau protein. CONCLUSION: In men, but not women, in the early stages of AD, CSF IGF-II level was elevated, and CSF IGFBP-2 level tended to be increased, compared to healthy controls.
BACKGROUND:Insulin-like growth factor-II (IGF-II) is important for brain development. Although IGF-II is abundant also in adult life, little is known of the role of IGF-II in Alzheimer's disease (AD). OBJECTIVE AND METHODS: This was a cross-sectional study of 60 consecutive patients under primary evaluation of cognitive impairment and 20 healthy controls. The patients had AD dementia or mild cognitive impairment (MCI) diagnosed with AD dementia upon follow-up (n = 32), stable MCI (SMCI, n = 13), or other dementias (n = 15). IGF-II, IGF-binding protein-1 (IGFBP-1), and IGFBP-2 were analyzed in serum and cerebrospinal fluid (CSF). RESULTS: Levels of IGF-II, IGFBP-1, and IGFBP-2 were similar in all groups in the total study population. Gender-specific analyses showed that in men (n = 40), CSF IGF-II level was higher in AD compared to SMCI and controls (p < 0.01 and p < 0.05, respectively). Furthermore, CSF IGFBP-2 level was increased in ADmen versus SMCI men (p < 0.01) and tended to be increased versus control men (p = 0.09). There were no between-group differences in women (n = 40). In the total study population (n = 80) as well as in men (n = 40), CSF levels of IGF-II and IGFBP-2 correlated positively with CSF levels of the AD biomarkers total-tau and phosphorylated tau protein. CONCLUSION: In men, but not women, in the early stages of AD, CSF IGF-II level was elevated, and CSF IGFBP-2 level tended to be increased, compared to healthy controls.
Authors: Luke W Bonham; Ethan G Geier; Natasha Z R Steele; Dominic Holland; Bruce L Miller; Anders M Dale; Rahul S Desikan; Jennifer S Yokoyama Journal: Front Neurosci Date: 2018-07-16 Impact factor: 4.677
Authors: Daniel Åberg; N David Åberg; Katarina Jood; Petra Redfors; Christian Blomstrand; Jörgen Isgaard; Christina Jern; Johan Svensson Journal: Life (Basel) Date: 2021-05-29
Authors: Annika Öhrfelt; Per Johansson; Anders Wallin; Ulf Andreasson; Henrik Zetterberg; Kaj Blennow; Johan Svensson Journal: Dement Geriatr Cogn Dis Extra Date: 2016-07-15
Authors: Emer R McGrath; Jayandra J Himali; Daniel Levy; Sarah C Conner; Charles S DeCarli; Matthew P Pase; Paul Courchesne; Claudia L Satizabal; Ramachandran S Vasan; Alexa S Beiser; Sudha Seshadri Journal: Ann Clin Transl Neurol Date: 2019-08-02 Impact factor: 4.511